{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT05191849",
      "OrgStudyIdInfo": {
        "OrgStudyId": "EXRNA-SCLC-2021"
      },
      "Organization": {
        "OrgFullName": "Fudan University",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Circulating EV Long RNA Profiles in SCLC",
      "OfficialTitle": "Circulating Extracellular Vesicle Long RNA Profiles in the Diagnosis and Prediction of Treatment Response for Small Cell Lung Cancer"
    },
    "StatusModule": {
      "StatusVerifiedDate": "December 2021",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "October 25, 2021",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "April 30, 2023",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "October 25, 2024",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "December 23, 2021",
      "StudyFirstSubmitQCDate": "January 10, 2022",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "January 14, 2022",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "January 10, 2022",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "January 14, 2022",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Jialei Wang",
        "ResponsiblePartyInvestigatorTitle": "Principal Investigator",
        "ResponsiblePartyInvestigatorAffiliation": "Fudan University"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Fudan University",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "To identify the circulating extracellular vesicle long RNA (exLR) profiles in small cell lung cancer (SCLC) and explore the potential of exLR as biomarkers to predict the therapeutic effect of SCLC."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Small Cell Lung Cancer"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Not Applicable"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Diagnostic",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "60",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Small Cell Lung Cancer receiving chemotherapy",
            "ArmGroupType": "Other",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Diagnostic Test: Blood sample collection"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Diagnostic Test",
            "InterventionName": "Blood sample collection",
            "InterventionDescription": "Baseline blood samples are collected before chemotherapy. Dynamic blood samples are also prospectively collected after 2~4 cycles of chemotherapy, or at the time of disease progression.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Small Cell Lung Cancer receiving chemotherapy"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Establish a model to predict curative effect",
            "PrimaryOutcomeDescription": "To detect the difference of exLR profiles of SCLC patients before and after treatment, and the difference of baseline exLR profiles between responders and non-responders.",
            "PrimaryOutcomeTimeFrame": "At the end of Cycle 4 (each cycle is 21 days)"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nPatients volunteered to participate in the study and have signed the informed consent.\nHistological or cytological diagnosis of small cell lung cancer, and no indication of radical surgery or radiotherapy.\nThere are measurable lesions defined by RECIST standard v1.1. A lesion can be considered measurable only if the previously irradiated lesion has clear progression after radiotherapy and the previous irradiated lesion is not the sole lesion.\nInitially treated patients who have not received any systematic therapy before. If have received postoperative adjuvant chemotherapy, the time to relapse is at least 6 months from the last adjuvant chemotherapy.\n18~75 years old; ECOG PS score: 0~1 points; expected survival time is more than 3 months.\nThe main organs's function meets the following criteria within 14 days before treatment:\n\n（1）Routine blood test (without blood transfusion within 14 days): a) Hemoglobin (HB) ≥ 90 g / L; b) Absolute neutrophil (ANC) ≥ 1.5 × 109 / L; c) Platelets (PLT) ≥ 80×109/L （2）Biochemical examination: a) Total bilirubin (TBIL) ≤ 1.5 times of the upper limit of the normal (ULN); b) Alanine aminotransferase (ALT) and aspartate aminotransferase AST ≤ 2.5ULN.To patients with liver metastasis, ALT and AST ≤ 5ULN; c) Serum creatinine (Cr) ≤ 1.5ULN or creatinine clearance (CCr) ≥ 60ml / min; （3）Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ the lower limit of the normal (50%).\n\n7. Patients with previously treated asymptomatic CNS metastases are allowed to participate in this study if all of the following criteria are met: a) No need for continuous corticosteroid therapy for CNS disease; b) No radiotherapy within 14 days prior to enrollment treatment; c) Imaging examination from the end of radiotherapy to screening period shows no CNS progression.\n\n8. Women of childbearing age should agree to conduct contraception (such as intrauterine devices, contraceptives or condoms) during the study and within 6 months after the end of the study; and the serum or urine pregnancy test is negative within 7 days prior to study enrollment and they must be non-lactating patients; Men should agree to conduct contraception during the study and within 6 months after the end of the study.\n\nExclusion Criteria:\n\nHistological or cytological diagnosis of small cell and non-small cell mixed lung cancer.\nPatients who have previously received systemic chemotherapy, signal transduction inhibitors, targeted therapies, hormone and endocrine therapy.\nPatients with other malignant tumors occurred within 5 years prior to the enrollment, except those with cured cervical carcinoma in situ and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)] , basal or squamous cell skin cancer, and localized prostate cancer and ductal breast carcinoma in situ treated with radical surgery.\nUnresolved toxicity due to any previous treatment above CTC AE (4.0) level 2 or higher, excluding hair loss.\nPatients with symptomatic CNS metastases.\nPatients with uncontrolled pleural, pericardial, or peritoneal effusion requiring repeated drainage.\n\nPatients with any severe and/or uncontrolled disease, including:\n\nPatients with unsatisfactory blood pressure control (systolic blood pressure >150 mmHg, diastolic blood pressure >90 mmHg).\nPatients with myocardial ischemia or myocardial infarction of Grade I of higher level, arrhythmia (including QTC ≥ 440ms) and congestive heart failure above Grade 2 (New York Heart Association (NYHA) classification).\nPatients with active or uncontrolled severe infection (≥ CTC AE Level 2).\nPatients with a history of immunodeficiency, including HIV-positive or other acquired, congenital immunodeficiency disease, or a history of organ transplantation.\nPatients with poor control of diabetes (fasting blood glucose (FBG)>10mmol/L).\nPatients with urine protein ≥ ++ indicated by routine urine test, and confirmed 24-hour urine protein quantitation > 1.0 g.\nPatients with seizures requiring treatment.\nPatients undergone venous thrombosis events currently or within 6 months, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis, and pulmonary embolism.\nPatients with a history of psychotropic drug abuse from which they are unable to abstain or with mental disorders.\nPatients who have participated in other clinical trials of anti-tumor drugs within four weeks.\nPatients with severe disease that threaten the safety of themselves or affect the completion of the study according to the investigators' judgment.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "75 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Jialei Wang, Doctor",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "18017312369",
            "CentralContactEMail": "luwangjialei@126.com"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Cancer hospital Fudan University",
            "LocationStatus": "Recruiting",
            "LocationCity": "Shanghai",
            "LocationState": "Shanghai",
            "LocationZip": "200032",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Jia lei Wang, Master",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "02164175590",
                  "LocationContactPhoneExt": "8907",
                  "LocationContactEMail": "luwangjialei@hotmail.com"
                }
              ]
            }
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 21, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000008175",
            "ConditionMeshTerm": "Lung Neoplasms"
          },
          {
            "ConditionMeshId": "D000055752",
            "ConditionMeshTerm": "Small Cell Lung Carcinoma"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000012142",
            "ConditionAncestorTerm": "Respiratory Tract Neoplasms"
          },
          {
            "ConditionAncestorId": "D000013899",
            "ConditionAncestorTerm": "Thoracic Neoplasms"
          },
          {
            "ConditionAncestorId": "D000009371",
            "ConditionAncestorTerm": "Neoplasms by Site"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000008171",
            "ConditionAncestorTerm": "Lung Diseases"
          },
          {
            "ConditionAncestorId": "D000012140",
            "ConditionAncestorTerm": "Respiratory Tract Diseases"
          },
          {
            "ConditionAncestorId": "D000002283",
            "ConditionAncestorTerm": "Carcinoma, Bronchogenic"
          },
          {
            "ConditionAncestorId": "D000001984",
            "ConditionAncestorTerm": "Bronchial Neoplasms"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M10324",
            "ConditionBrowseLeafName": "Lung Neoplasms",
            "ConditionBrowseLeafAsFound": "Lung Cancer",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M27476",
            "ConditionBrowseLeafName": "Small Cell Lung Carcinoma",
            "ConditionBrowseLeafAsFound": "Small Cell Lung Cancer",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M4686",
            "ConditionBrowseLeafName": "Carcinoma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14131",
            "ConditionBrowseLeafName": "Respiratory Tract Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M15810",
            "ConditionBrowseLeafName": "Thoracic Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10320",
            "ConditionBrowseLeafName": "Lung Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14129",
            "ConditionBrowseLeafName": "Respiratory Tract Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4692",
            "ConditionBrowseLeafName": "Carcinoma, Bronchogenic",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4412",
            "ConditionBrowseLeafName": "Bronchial Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T5271",
            "ConditionBrowseLeafName": "Small Cell Lung Cancer",
            "ConditionBrowseLeafAsFound": "Small Cell Lung Cancer",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC08",
            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}